Santangelo Andrea, Bartolini Emanuele, Nuzzi Giulia, Foiadelli Thomas, Michev Alexandre, Mina Tommaso, Trambusti Irene, Fichera Valeria, Bonuccelli Alice, Massimetti Gabriele, Peroni Diego G, De Marco Emanuela, Coccoli Luca, Luti Laura, Bernasconi Sayla, Nardi Margherita, Menconi Maria Cristina, Casazza Gabriella, Pruna Dario, Mura Rosamaria, Marra Chiara, Zama Daniele, Striano Pasquale, Cordelli Duccio M, Battini Roberta, Orsini Alessandro
Paediatric Neurology, Paediatric Department, Santa Chiara University Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Department of Developmental Neuroscience, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Fondazione Stella Maris, Pisa, Italy.
Front Neurol. 2022 Jun 10;13:920214. doi: 10.3389/fneur.2022.920214. eCollection 2022.
Stroke-like syndrome (SLS) is a rare subacute neurological complication of intrathecal or high-dose (≥500 mg) Methotrexate (MTX) administration. Its clinical features, evoking acute cerebral ischaemia with fluctuating course symptoms and a possible spontaneous resolution, have elicited interest among the scientific community. However, many issues are still open on the underlying pathogenesis, clinical, and therapeutic management and long-term outcome.
We retrospectively analyzed clinical, radiological and laboratory records of all patients diagnosed with SLS between 2011 and 2021 at 4 National referral centers for Pediatric Onco-Hematology. Patients with a latency period that was longer than 3 weeks between the last MTX administration of MTX and SLS onset were excluded from the analysis, as were those with unclear etiologies. We assessed symptom severity using a dedicated arbitrary scoring system. Eleven patients were included in the study.
The underlying disease was acute lymphoblastic leukemia type B in 10/11 patients, while fibroblastic osteosarcoma was present in a single subject. The median age at diagnosis was 11 years (range 4-34), and 64% of the patients were women. Symptoms occurred after a mean of 9.45 days (± 0.75) since the last MTX administration and lasted between 1 and 96 h. Clinical features included hemiplegia and/or cranial nerves palsy, paraesthesia, movement or speech disorders, and seizure. All patients underwent neuroimaging studies (CT and/or MRI) and EEG. The scoring system revealed an average of 4.9 points (± 2.3), with a median of 5 points (maximum 20 points). We detected a linear correlation between the severity of the disease and age in male patients.
SLS is a rare, well-characterized complication of MTX administration. Despite the small sample, we have been able to confirm some of the previous findings in literature. We also identified a linear correlation between age and severity of the disease, which could improve the future clinical management.
类卒中综合征(SLS)是鞘内注射或高剂量(≥500毫克)甲氨蝶呤(MTX)给药后的一种罕见的亚急性神经并发症。其临床特征引发急性脑缺血,伴有症状波动且可能自发缓解,这引起了科学界的关注。然而,关于其潜在发病机制、临床和治疗管理以及长期预后仍存在许多问题。
我们回顾性分析了2011年至2021年期间在4个国家儿童肿瘤血液学转诊中心诊断为SLS的所有患者的临床、放射学和实验室记录。末次MTX给药与SLS发病间隔时间超过3周的患者以及病因不明的患者被排除在分析之外。我们使用专门的任意评分系统评估症状严重程度。11名患者纳入研究。
11名患者中有10名潜在疾病为B型急性淋巴细胞白血病,1名患者为成纤维细胞性骨肉瘤。诊断时的中位年龄为11岁(范围4 - 34岁),64%的患者为女性。症状出现在末次MTX给药后平均9.45天(±0.75),持续1至96小时。临床特征包括偏瘫和/或颅神经麻痹、感觉异常、运动或言语障碍以及癫痫发作。所有患者均接受了神经影像学检查(CT和/或MRI)以及脑电图检查。评分系统显示平均得分为4.9分(±2.3),中位数为5分(满分20分)。我们在男性患者中检测到疾病严重程度与年龄之间存在线性相关性。
SLS是MTX给药罕见且特征明确的并发症。尽管样本量小,但我们能够证实文献中先前的一些发现。我们还发现年龄与疾病严重程度之间存在线性相关性,这可能会改善未来的临床管理。